New treatment option for psoriatic arthritis

Patients with psoriatic arthritis experienced improved disease activity, better physical function and less joint damage after treatment with ixekizumab, according to trial results.

Compared with placebo, considerably more patients on ixekizumab achieved an ACR20 response by six months, data showed.

They also had significantly less progression of joint damage and greater clearance of plaque